Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
about
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesHistones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.T-oligos inhibit growth and induce apoptosis in human ovarian cancer cellsEpigenomics of ovarian cancer and its chemoprevention.The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cellsFunctional redundancy of the Notch pathway in ovarian cancer cell lines.New players in ovarian cancer.Targeting the epigenome in ovarian cancer.Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line.Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells.
P2860
Q30570945-F0C4940A-DE66-4E5C-88BC-83EA31DA5269Q33741828-9DB54F1E-76D6-4748-8B81-B9C800252435Q34409219-D8D1F921-62E3-4CB0-B5F4-1428F8BA63E6Q34638065-06B5C109-FA76-49CE-94FF-4C7C03A7E9DFQ35048659-B20F7F4A-9DE4-4A55-AC75-4E7CCBE47E6EQ35711392-D73C2B40-E1A8-4104-ACE2-58A56F519548Q36063233-8756E3AA-9F35-4DF9-BFE1-4C18DB1E1540Q36129967-0D7D2C5B-746E-4410-BC89-BAFB25319855Q37289384-37DB36AE-FB13-4F50-9E98-E81FCCCE328CQ37837735-00105E46-ECEA-44DE-AAFB-4DC8CC643BFCQ37984122-E9E6BDA1-A851-4D7D-92ED-17A35854C727Q38844777-37F814BF-0FF0-4C9C-8BE5-8C38B95B6959Q38975491-17D2EE57-5DEC-4170-88AD-BFE3509EFF0FQ39430288-D035CC5D-DDAE-4C1F-A044-A98295367753Q42378478-C7243616-8D39-46F3-8A8A-5D0C9DBDCC30
P2860
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
@ast
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
@en
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
@nl
type
label
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
@ast
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
@en
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
@nl
prefLabel
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
@ast
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
@en
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
@nl
P2860
P356
P1433
P1476
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
@en
P2093
Hisashi Narahara
Noriyuki Takai
P2860
P304
P356
10.1155/2010/458431
P577
2009-12-20T00:00:00Z